501 related articles for article (PubMed ID: 19284577)
1. Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis.
Chen YS; Yan W; Geczy CL; Brown MA; Thomas R
Arthritis Res Ther; 2009; 11(2):R39. PubMed ID: 19284577
[TBL] [Abstract][Full Text] [Related]
2. [S100A8, S100A9 and S100A12 proteins in rheumatoid arthritis].
Baillet A
Rev Med Interne; 2010 Jun; 31(6):458-61. PubMed ID: 20398973
[TBL] [Abstract][Full Text] [Related]
3. Calprotectin (S100A8/A9) and S100A12 are associated with measures of disease activity in a longitudinal study of patients with rheumatoid arthritis treated with infliximab.
Nordal HH; Brun JG; Hordvik M; Eidsheim M; Jonsson R; Halse AK
Scand J Rheumatol; 2016 Jul; 45(4):274-81. PubMed ID: 26767827
[TBL] [Abstract][Full Text] [Related]
4. Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease.
Leach ST; Yang Z; Messina I; Song C; Geczy CL; Cunningham AM; Day AS
Scand J Gastroenterol; 2007 Nov; 42(11):1321-31. PubMed ID: 17852869
[TBL] [Abstract][Full Text] [Related]
5. Plasma S100A12 and soluble receptor of advanced glycation end product levels and mortality in chronic kidney disease Stage 5 patients.
Isoyama N; Leurs P; Qureshi AR; Bruchfeld A; Anderstam B; Heimburger O; Bárány P; Stenvinkel P; Lindholm B
Nephrol Dial Transplant; 2015 Jan; 30(1):84-91. PubMed ID: 25074436
[TBL] [Abstract][Full Text] [Related]
6. Monomeric calgranulins measured by SELDI-TOF mass spectrometry and calprotectin measured by ELISA as biomarkers in arthritis.
de Seny D; Fillet M; Ribbens C; Marée R; Meuwis MA; Lutteri L; Chapelle JP; Wehenkel L; Louis E; Merville MP; Malaise M
Clin Chem; 2008 Jun; 54(6):1066-75. PubMed ID: 18436720
[TBL] [Abstract][Full Text] [Related]
7. Soluble receptor for advanced glycation endproducts is decreased in patients with juvenile idiopathic arthritis (ERA category) and inversely correlates with disease activity and S100A12 levels.
Myles A; Viswanath V; Singh YP; Aggarwal A
J Rheumatol; 2011 Sep; 38(9):1994-9. PubMed ID: 21724696
[TBL] [Abstract][Full Text] [Related]
8. Circulating levels of soluble receptor for advanced glycation end product are inversely associated with vascular calcification in patients on haemodialysis independent of S100A12 (EN-RAGE) levels.
Kim HS; Chung W; Kim AJ; Ro H; Chang JH; Lee HH; Jung JY
Nephrology (Carlton); 2013 Dec; 18(12):777-82. PubMed ID: 24124651
[TBL] [Abstract][Full Text] [Related]
9. Acute Kawasaki disease is associated with reverse regulation of soluble receptor for advance glycation end products and its proinflammatory ligand S100A12.
Wittkowski H; Hirono K; Ichida F; Vogl T; Ye F; Yanlin X; Saito K; Uese K; Miyawaki T; Viemann D; Roth J; Foell D
Arthritis Rheum; 2007 Dec; 56(12):4174-81. PubMed ID: 18050248
[TBL] [Abstract][Full Text] [Related]
10. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein.
Basta G; Sironi AM; Lazzerini G; Del Turco S; Buzzigoli E; Casolaro A; Natali A; Ferrannini E; Gastaldelli A
J Clin Endocrinol Metab; 2006 Nov; 91(11):4628-34. PubMed ID: 16926247
[TBL] [Abstract][Full Text] [Related]
11. Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control.
Pullerits R; Bokarewa M; Dahlberg L; Tarkowski A
Arthritis Res Ther; 2005; 7(4):R817-24. PubMed ID: 15987483
[TBL] [Abstract][Full Text] [Related]
12. Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients.
Nakashima A; Carrero JJ; Qureshi AR; Miyamoto T; Anderstam B; Bárány P; Heimbürger O; Stenvinkel P; Lindholm B
Clin J Am Soc Nephrol; 2010 Dec; 5(12):2213-9. PubMed ID: 20847094
[TBL] [Abstract][Full Text] [Related]
13. Increased serum levels of S100A8/A9 and S100A12 are associated with cardiovascular disease in patients with inactive systemic lupus erythematosus.
Tydén H; Lood C; Gullstrand B; Jönsen A; Nived O; Sturfelt G; Truedsson L; Ivars F; Leanderson T; Bengtsson AA
Rheumatology (Oxford); 2013 Nov; 52(11):2048-55. PubMed ID: 23942785
[TBL] [Abstract][Full Text] [Related]
14. Decreases in serum levels of S100A8/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis.
Andrés Cerezo L; Mann H; Pecha O; Pleštilová L; Pavelka K; Vencovský J; Senolt L
Arthritis Res Ther; 2011 Jul; 13(4):R122. PubMed ID: 21791097
[TBL] [Abstract][Full Text] [Related]
15. Elevated S100A8/A9 and S100A12 Serum Levels Reflect Intraocular Inflammation in Juvenile Idiopathic Arthritis-Associated Uveitis: Results From a Pilot Study.
Walscheid K; Heiligenhaus A; Holzinger D; Roth J; Heinz C; Tappeiner C; Kasper M; Foell D
Invest Ophthalmol Vis Sci; 2015 Dec; 56(13):7653-60. PubMed ID: 26624497
[TBL] [Abstract][Full Text] [Related]
16. S100A8 and S100A12 Proteins as Biomarkers of High Disease Activity in Patients with Rheumatoid Arthritis That Can Be Regulated by Epigenetic Drugs.
Roszkowski L; Jaszczyk B; Plebańczyk M; Ciechomska M
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614150
[TBL] [Abstract][Full Text] [Related]
17. S100A8/A9 as a biomarker for synovial inflammation and joint damage in patients with rheumatoid arthritis.
Kang KY; Woo JW; Park SH
Korean J Intern Med; 2014 Jan; 29(1):12-9. PubMed ID: 24574827
[TBL] [Abstract][Full Text] [Related]
18. Systemic levels of the anti-inflammatory decoy receptor soluble RAGE (receptor for advanced glycation end products) are decreased in dogs with inflammatory bowel disease.
Heilmann RM; Otoni CC; Jergens AE; Grützner N; Suchodolski JS; Steiner JM
Vet Immunol Immunopathol; 2014 Oct; 161(3-4):184-92. PubMed ID: 25183017
[TBL] [Abstract][Full Text] [Related]
19. Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer.
Hermani A; Hess J; De Servi B; Medunjanin S; Grobholz R; Trojan L; Angel P; Mayer D
Clin Cancer Res; 2005 Jul; 11(14):5146-52. PubMed ID: 16033829
[TBL] [Abstract][Full Text] [Related]
20. Reverse regulation of soluble receptor for advanced glycation end products and proinflammatory factor resistin and S100A12 in Kawasaki disease.
Qi Y; Gong F; Zhang Q; Xie C; Wang W; Fu S
Arthritis Res Ther; 2012 Nov; 14(6):R251. PubMed ID: 23171632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
